Abstract
Cells of the innate immune system interact with pathogens via conserved pattern-recognition receptors, whereas cells of the adaptive immune system recognize pathogens through diverse, antigen-specific receptors that are generated by somatic DNA rearrangement. Invariant natural killer T (iNKT) cells are a subset of lymphocytes that bridge the innate and adaptive immune systems. Although iNKT cells express T cell receptors that are generated by somatic DNA rearrangement, these receptors are semi-invariant and interact with a limited set of lipid and glycolipid antigens, thus resembling the pattern-recognition receptors of the innate immune system. Functionally, iNKT cells most closely resemble cells of the innate immune system, as they rapidly elicit their effector functions following activation, and fail to develop immunological memory. iNKT cells can become activated in response to a variety of stimuli and participate in the regulation of various immune responses. Activated iNKT cells produce several cytokines with the capacity to jump-start and modulate an adaptive immune response. A variety of glycolipid antigens that can differentially elicit distinct effector functions in iNKT cells have been identified. These reagents have been employed to test the hypothesis that iNKT cells can be harnessed for therapeutic purposes in human diseases. Here, we review the innate-like properties and functions of iNKT cells and discuss their interactions with other cell types of the immune system.
Similar content being viewed by others
References
Abbas AK, Lichtman AH, Pillai S (2010) Cellular and molecular immunology, 6th edn. Saunders, Philadelphia, PA
Amprey JL, Im JS, Turco SJ, Murray HW, Illarionov PA, Besra GS, Porcelli SA, Spath GF (2004) A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J Exp Med 200:895–904
Arrenberg P, Halder R, Kumar V (2009) Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens. J Cell Physiol 218:246–250
Bai L, Sagiv Y, Liu Y, Freigang S, Yu KO, Teyton L, Porcelli SA, Savage PB, Bendelac A (2009) Lysosomal recycling terminates CD1d-mediated presentation of short and polyunsaturated variants of the NKT cell lipid antigen αGalCer. Proc Natl Acad Sci USA 106:10254–10259
Barral P, Polzella P, Bruckbauer A, van Rooijen N, Besra GS, Cerundolo V, Batista FD (2010) CD169+ macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat Immunol 11:303–312
Behar SM, Porcelli SA (2007) CD1-restricted T cells in host defense to infectious diseases. Curr Top Microbiol Immunol 314:215–250
Bendelac A, Bonneville M, Kearney JF (2001) Autoreactivity by design: innate B and T lymphocytes. Nat Rev Immunol 1:177–186
Bendelac A, Savage PB, Teyton L (2007) The biology of NKT cells. Annu Rev Immunol 25:297–336
Bezbradica JS, Stanic AK, Matsuki N, Bour-Jordan H, Bluestone JA, Thomas JW, Unutmaz D, Van Kaer L, Joyce S (2005) Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol 174:4694–4705
Brigl M, Brenner MB (2004) CD1: antigen presentation and T cell function. Annu Rev Immunol 22:817–890
Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB (2003) Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 4:1230–1237
Brutkiewicz RR (2006) CD1d ligands: the good, the bad, and the ugly. J Immunol 177:769–775
Cerundolo V, Salio M (2007) Harnessing NKT cells for therapeutic applications. Curr Top Microbiol Immunol 314:325–340
Cerundolo V, Silk JD, Masri SH, Salio M (2009) Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 9:28–38
Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, Hutchinson A, Geller M, Liu N, Annable R, Shay J, Kirchhoff K, Nishi N, Ando Y, Hayashi K, Hassoun H, Steinman RM, Dhodapkar MV (2005) Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosylceramide loaded mature dendritic cells in cancer patients. J Exp Med 201:1503–1517
Chang WS, Kim JY, Kim YJ, Kim YS, Lee JM, Azuma M, Yagita H, Kang CY (2008) Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 181:6707–6710
Chiba A, Dascher CC, Besra GS, Brenner MB (2008) Rapid NKT cell responses are self-terminating during the course of microbial infection. J Immunol 181:2292–2302
Choi HJ, Xu H, Geng Y, Colmone A, Cho H, Wang CR (2008) Bacterial infection alters the kinetics and function of iNKT cell responses. J Leukoc Biol 84:1462–1471
Coppieters K, Dewint P, Van Beneden K, Jacques P, Seeuws S, Verbruggen G, Deforce D, Elewaut D (2007a) NKT cells: manipulable managers of joint inflammation. Rheumatology 46:565–571
Coppieters K, Van Beneden K, Jacques P, Dewint P, Vervloet A, Vander Cruyssen B, Van Calenbergh S, Chen G, Franck RW, Verbruggen G, Deforce D, Matthys P, Tsuji M, Rottiers P, Elewaut D (2007b) A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner. J Immunol 179:2300–2309
Coquet JM, Chakravarti S, Kyparissoudis K, McNab FW, Pitt LA, McKenzie BS, Berzins SP, Smyth MJ, Godfrey DI (2008) Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci USA 105:11287–11292
Crowe NY, Uldrich AP, Kyparissoudis K, Hammond KJL, Hayakawa K, Sidobre S, Keating R, Kronenberg M, Smyth MJ, Godfrey DI (2003) Glycolipid antigen drives rapid expansion and sustained cytokine production by NKT cells. J Immunol 171:4020–4027
Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG, Hayakawa Y, Godfrey DI, Smyth MJ (2005) Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 202:1279–1288
Driver JP, Scheuplein F, Chen YG, Grier AE, Wilson SB, Serreze DV (2010) Invariant natural killer T-cell control of type 1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian roulette. Diabetes 59:423–432
Faveeuw C, Angeli V, Fontaine J, Maliszewski C, Capron A, Van Kaer L, Moser M, Capron M, Trottein F (2002) Antigen presentation by CD1d contributes to the amplification of Th2 responses to Schistosoma mansoni glycoconjugates in mice. J Immunol 169:906–912
Fischer K, Scotet E, Niemeyer M, Koebernick H, Zerrahn J, Maillet S, Hurwitz R, Kursar M, Bonneville M, Kaufmann SHE, Schaible UE (2004) Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc Natl Acad Sci USA 101:10685–10690
Fox LM, Cox DG, Lockridge JL, Wang X, Chen X, Scharf L, Trott DL, Ndonye RM, Veerapen N, Besra GS, Howell AR, Cook ME, Adams EJ, Hildebrand WH, Gumperz JE (2009) Recognition of lyso-phospholipids by human natural killer T lymphocytes. PLoS Biol 7:e1000228
Fujii S (2008) Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies. Trends Immunol 29:242–249
Fujii S, Shimizu K, Kronenberg M, Steinman RM (2002) Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide-loaded DCs. Nat Immunol 3:867–874
Gabriel CL, Wu L, Parekh VV, Van Kaer L (2010) Invariant natural killer T cell-based therapy of autoimmune diseases. Curr Immunol Rev 6:88–101
Gapin L (2010) iNKT cell autoreactivity: what is 'self' and how is it recognized? Nat Rev Immunol 10:272–277
Giaccone G, Punt CJA, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BME, Scheper RJ, van der Vliet HJJ, van den Eertwegh AJM, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM (2002) A phase I study of natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8:3702–3709
Godfrey DI, Kronenberg M (2004) Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 114:1379–1388
Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L (2004) NKT cells: what's in a name? Nat Rev Immunol 4:231–237
Godfrey DI, Stankovic S, Baxter AG (2010) Raising the NKT cell family. Nat Immunol 11:197–206
Grajewski RS, Hansen AM, Agarwal RK, Kronenberg M, Sidobre S, Su SB, Silver PB, Tsuji M, Franck RW, Lawton AP, Chan CC, Caspi RR (2008) Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses. J Immunol 181:4791–4797
Gumperz JE, Roy C, Makowska A, Lum D, Sugita M, Podrebarac T, Koezuka Y, Porcelli SA, Cardell S, Brenner MB, Behar SM (2000) Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12:211–221
Gumperz JE, Miyake S, Yamamura T, Brenner MB (2002) Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 195:625–636
Halder RC, Aguilera C, Maricic I, Kumar V (2007) Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 117:2302–2312
Harada M, Seino KI, Wakao H, Sakata S, Ishizuka Y, Ito T, Kojo S, Nakayama T, Taniguchi M (2004) Down-regulation of the invariant Vα14 antigen receptor in NKT cells upon activation. Int Immunol 16:241–247
Haraguchi K, Takahashi T, Matsumoto A, Asai T, Kanda Y, Kurokawa M, Ogawa S, Oda H, Taniguchi M, Hirai H, Chiba S (2005) Host-residual invariant NK T cells attenuate graft-versus-host immunity. J Immunol 175:1320–1328
Hashimoto D, Asakura S, Miyake S, Yamamura T, Van Kaer L, Liu C, Tanimoto M, Teshima T (2005) Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J Immunol 174:551–556
Im JS, Arora P, Bricard G, Molano A, Venkataswamy MM, Baine I, Jerud ES, Goldberg MF, Baena A, Yu KO, Ndonye RM, Howell AR, Yuan W, Cresswell P, Chang YT, Illarionov PA, Besra GS, Porcelli SA (2009) Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity 30:888–898
Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, Koezuka Y, Kumar V (2001) Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 194:1789–1799
Johnson TR, Hong S, Van Kaer L, Koezuka Y, Graham BS (2002) NK T cells contribute to expansion of CD8+ T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol 76:4294–4303
Joshi SK, Lang GA, Larabee JL, Devera TS, Aye LM, Shah HB, Ballard JD, Lang ML (2009) Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy. PLoS Pathog 5:e1000588
Joyce S, Van Kaer L (2008) Invariant natural killer T cells trigger adaptive lymphocytes to churn up bile. Cell Host Microbe 3:275–277
Joyee AG, Qiu H, Wang S, Fan Y, Bilenki L, Yang X (2007) Distinct NKT cell subsets are induced by different Chlamydia species leading to differential adaptive immunity and host resistance to the infections. J Immunol 178:1048–1058
Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M (1997) CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278:1626–1629
Kim S, Lalani S, Parekh VV, Vincent TL, Wu L, Van Kaer L (2008a) Impact of bacteria on the phenotype, functions and therapeutic activities of iNKT cells in mice. J Clin Invest 118:2301–2315
Kim S, Lalani S, Parekh VV, Wu L, Van Kaer L (2008b) Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants. Expert Rev Vaccines 7:1519–1532
Kinjo Y, Wu DY, Kim G, Xing G-W, Poles MA, Ho DD, Tsuji M, Kawahara K, Wong C-H, Kronenberg M (2005) Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434:520–525
Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, Benhnia M, Zajonc DM, Ben-Menachem G, Ainge GD, Painter GF, Khurana A, Hoebe K, Behar SM, Buetler B, Wilson IA, Tsuji M, Sellati TJ, Wong CH, Kronenberg M (2006) Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol 7:978–986
Kojo S, Elly C, Harada Y, Langdon WY, Kronenberg M, Liu YC (2009) Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination of CARMA1. Proc Natl Acad Sci USA 106:17847–17851
Kovalovsky D, Uche OU, Eladad S, Hobbs RM, Yi W, Alonzo E, Chua K, Eidson M, Kim HJ, Im JS, Pandolfi PP, Sant'Angelo DB (2008) The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol 9:1055–1064
Kronenberg M (2005) Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 26:877–900
Kuns RD, Morris ES, Macdonald KP, Markey KA, Morris HM, Raffelt NC, Banovic T, Don AL, Rowe V, Burman AC, Clouston AD, Farah C, Besra GS, Illarionov PA, Smyth MJ, Porcelli SA, Hill GR (2009) Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after α-galactosylceramide administration. Blood 113:5999–6010
La Cava A, Van Kaer L, Shi FD (2006) CD4+CD25+ Tregs and NKT cells: regulators regulating regulators. Trends Immunol 27:322–327
Lee PT, Benlagha K, Teyton L, Bendelac A (2002) Distinct functional lineages of human Vα24 natural killer T cells. J Exp Med 195:637–641
Lombardi V, Stock P, Singh AK, Kerzerho J, Yang W, Sullivan BA, Li X, Shiratsuchi T, Hnatiuk NE, Howell AR, Yu KO, Porcelli SA, Tsuji M, Kronenberg M, Wilson SB, Akbari O (2010) A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. J Immunol 184:2107–2115
Lotter H, Gonzalez-Roldan N, Lindner B, Winau F, Isibasi A, Moreno-Lafont M, Ulmer AJ, Holst O, Tannich E, Jacobs T (2009) Natural killer T cells activated by a lipopeptidophosphoglycan from Entamoeba histolytica are critically important to control amebic liver abscess. PLoS Pathog 5:e1000434
Major AS, Joyce S, Van Kaer L (2006) Lipid metabolism, atherogenesis and CD1-restricted antigen presentation. Trends Mol Med 12:270–278
Mallevaey T, Zanetta JP, Faveeuw C, Fontaine J, Maes E, Platt F, Capron M, de-Moraes ML, Trottein F (2006) Activation of invariant NKT cells by the helminth parasite Schistosoma mansoni. J Immunol 176:2476–2485
Matsuda JL, Gapin L, Baron JL, Sidobre S, Stetson DB, Mohrs M, Locksley RM, Kronenberg M (2003) Mouse Vα14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci USA 100:8395–8400
Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L (2008) CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr Opin Immunol 20:358–368
Mattner J, DeBord KL, Ismail N, Goff RD, Cantu CI, Zhou D, Saint-Mezard P, Wang V, Gao Y, Yin N, Hoebe K, Schneewind O, Walker D, Buetler B, Teyton L, Savage PB, Bendelac A (2005) Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434:525–529
Meyer EH, DeKruyff RH, Umetsu DT (2007) iNKT cells in allergic disease. Curr Top Microbiol Immunol 314:269–291
Michel ML, Keller AC, Paget C, Fujio M, Trottein F, Savage PB, Wong CH, Schneider E, Dy M, Leite-de-Moraes MC (2007) Identification of an IL-17-producing NK1.1- iNKT cell population involved in airway neutrophilia. J Exp Med 204:995–1001
Motohashi S, Nakayama T (2008) Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci 99:638–645
Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, Nakayama T (2009) A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 182:2492–2501
Muindi K, Cernadas M, Watts GF, Royle L, Neville DC, Dwek RA, Besra GS, Rudd PM, Butters TD, Brenner MB (2010) Activation state and intracellular trafficking contribute to the repertoire of endogenous glycosphingolipids presented by CD1d. Proc Natl Acad Sci USA 107:3052–3057
Murphy K, Travers P, Walport M (2007) Janeway's immunobiology, 7th edn. Garland, New York, NY
Nagarajan NA, Kronenberg M (2007) Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J Immunol 178:2706–2713
Naidenko OV, Maher JK, Ernst WA, Sakai T, Modlin RL, Kronenberg M (1999) Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules. J Exp Med 190:1069–1080
Natori T, Koezuka Y, Higa T (1993) Agelasphins, novel α-galactosylceramides from the marine sponge Agelas mauritianus. Tetrahedron Lett 34:5591–5592
Nieda M, Okai M, Tazbirkova A, Lin H, Yamauro A, Ide K, Abraham R, Juji T, Macfarlane DJ, Nicol AJ (2004) Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103:383–389
Nieuwenhuis EE, Matsumoto T, Lindenbergh D, Willemsen R, Kaser A, Simons-Oosterhuis Y, Brugman S, Yamaguchi K, Ishikawa H, Aiba Y, Koga Y, Samsom JN, Oshima K, Kikuchi M, Escher JC, Hattori M, Onderdonk AB, Blumberg RS (2009) Cd1d-dependent regulation of bacterial colonization in the intestine of mice. J Clin Invest 119:1241–1250
Nieuwenhuis EES, Gillessen S, Scheper RJ, Exley MA, Taniguchi M, Balk SP, Strominger JL, Dranoff G, Blumberg RS, Wilson SB (2005) CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity. Exp Dermatol 14:250–258
Nowak M, Stein-Streilein J (2007) Invariant NKT cells and tolerance. Int Rev Immunol 26:95–119
Oki S, Chiba A, Yamamura T, Miyake S (2004) The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest 113:1631–1640
Osman Y, Kawamura T, Naito T, Takeda K, Van Kaer L, Okumura K, Abo T (2000) Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur J Immunol 30:1919–1928
Paget C, Mallevaey T, Speak AO, Torres D, Fontaine J, Sheehan KC, Capron M, Ryffel B, Faveeuw C, Leite de Moraes M, Platt F, Trottein F (2007) Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity 27:597–609
Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang C-R, Joyce S, Van Kaer L (2005) Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 115:2572–2583
Parekh VV, Lalani S, Van Kaer L (2007) The in vivo response of invariant natural killer T cells to glycolipid antigens. Int Rev Immunol 26:31–48
Parekh VV, Lalani S, Kim S, Halder R, Azuma M, Yagita H, Kumar V, Wu L, Kaer LV (2009) PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol 182:2816–2826
Pillai AB, George TI, Dutt S, Teo P, Strober S (2007) Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol 178:6242–6251
Raghuraman G, Geng Y, Wang C-R (2006) IFN-β-mediated up-regulation of CD1d in bacteria-infected APCs. J Immunol 177:7841–7848
Rodgers JR, Cook RG (2005) MHC class Ib molecules bridge innate and acquired immunity. Nat Rev Immunol 5:459–471
Salio M, Speak AO, Shepherd D, Polzella P, Illarionov PA, Veerapen N, Besra GS, Platt FM, Cerundolo V (2007) Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. Proc Natl Acad Sci USA 104:20490–20495
Savage AK, Constantinides MG, Han J, Picard D, Martin E, Li B, Lantz O, Bendelac A (2008) The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 29:391–403
Schmieg J, Yang G, Franck RW, Tsuji M (2003) Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J Exp Med 198:1631–1641
Schmieg J, Yang G, Franck RW, Van Rooijen N, Tsuji M (2005) Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc Natl Acad Sci USA 102:1127–1132
Singh AK, Yang J-Q, Parekh VV, Wei J, Wang C-R, Joyce S, Singh RR, Van Kaer L (2005) The natural killer T cell ligand α-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur J Immunol 35:1143–1154
Sireci G, Russo D, Dieli F, Porcelli SA, Taniguchi M, La Manna MP, Di Liberto D, Scarpa F, Salerno A (2007) Immunoregulatory role of Jα281 T cells in aged mice developing lupus-like nephritis. Eur J Immunol 37:425–433
Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR (2005) Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur J Immunol 35:1692–1701
Stetson DB, Mohrs M, Reinhardt RL, Baron JL, Wang ZE, Gapin L, Kronenberg M, Locksley RM (2003) Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med 198:1069–1076
Sullivan BA, Nagarajan NA, Wingender G, Wang J, Scott I, Tsuji M, Franck RW, Porcelli SA, Zajonc DM, Kronenberg M (2010) Mechanisms for glycolipid antigen-driven cytokine polarization by Vα14i NKT cells. J Immunol 184:141–153
Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H (2003) The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21:483–513
Tashiro T, Sekine-Kondo E, Shigeura T, Nakagawa R, Inoue S, Omori-Miyake M, Chiba T, Hongo N, Fujii S, Shimizu K, Yoshiga Y, Sumida T, Mori K, Watarai H, Taniguchi M (2010) Induction of Th1-biased cytokine production by α-carba-GalCer, a neoglycolipid ligand for NKT cells. Int Immunol 22:319–328
Terabe M, Berzofsky JA (2008) The role of NKT cells in tumor immunity. Adv Cancer Res 101:277–348
Tupin E, Kinjo T, Kronenberg M (2007) The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 5:405–417
Ulrich AP, Crowe NY, Kyparissoudis K, Pellicci DG, Zhan Y, Lew AM, Bouillet P, Strasser A, Smyth MJ, Godfrey DI (2005) NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol 175:3092–3101
Van Kaer L (2005) α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 5:31–42
Van Kaer L (2007) NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol 19:354–364
Varthaman A, Khallou-Laschet J, Clement M, Fornasa G, Kim HJ, Gaston AT, Dussiot M, Caligiuri G, Herbelin A, Kaveri S, Cantor H, Nicoletti A (2010) Control of T cell reactivation by regulatory Qa-1-restricted CD8+ T cells. J Immunol 184:6585–6591
Veldt BJ, van der Vliet HJ, von Blomberg BM, van Vlierberghe H, Gerken G, Nishi N, Hayashi K, Scheper RJ, de Knegt RJ, van den Eertwegh AJ, Janssen HL, van Nieuwkerk CM (2007) Randomized placebo controlled phase I/II trial of α-galactosylceramide for the treatment of chronic hepatitis C. J Hepatol 47:356–365
Venkataswamy MM, Porcelli SA (2010) Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin Immunol 22:68–78
Wilson MT, Singh AK, Van Kaer L (2002) Immunotherapy with ligands of natural killer T cells. Trends Mol Med 8:225–231
Wilson MT, Johansson C, Olivares-Villagomez D, Singh AK, Stanic AK, Wang CR, Joyce S, Wick MJ, Van Kaer L (2003) The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 100:10913–10918
Woltman AM, Ter Borg MJ, Binda RS, Sprengers D, von Blomberg BM, Scheper RJ, Hayashi K, Nishi N, Boonstra A, van der Molen R, Janssen HL (2009) α-Galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir Ther 14:809–818
Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB (2003) Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 198:173–181
Yu KO, Im JS, Molano A, Dutronc Y, Illarionov PA, Forestier C, Fujiwara N, Arias I, Miyake S, Yamamura T, Chang YT, Besra GS, Porcelli SA (2005) Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc Natl Acad Sci USA 102:3383–3388
Zhou D, Mattner J, Cantu C, Schrantz N, Yin N, Gao Y, Sagiv Y, Hudspeth K, Wu Y, Yamashita T, Teneberg S, Wang D, Proia R, Levery SB, Savage PB, Teyton L, Bendelac A (2004) Lysosomal glycosphingolipid recognition by NKT cells. Science 306:1786–1789
Acknowledgements
We apologize to colleagues whose work we did not cite due to space constraints or omission. We thank many colleagues, especially Dr. Sebastian Joyce (Vanderbilt University School of Medicine), for helpful discussions.
Author information
Authors and Affiliations
Corresponding author
Additional information
Funding
The authors’ work was supported by grants from the National Institutes of Health (to L.V.K. and L.W.), a discovery grant from the Diabetes Research and Training Center at Vanderbilt University School of Medicine (to L.W.), and a postdoctoral fellowship from the National Multiple Sclerosis Society (to V.V.P.).
Rights and permissions
About this article
Cite this article
Van Kaer, L., Parekh, V.V. & Wu, L. Invariant natural killer T cells: bridging innate and adaptive immunity. Cell Tissue Res 343, 43–55 (2011). https://doi.org/10.1007/s00441-010-1023-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00441-010-1023-3